Clinical trials: Antithrombotic
Complication
Perioperative Safety of Bladder Hydrodistension in Patients on Antithrombotic Therapy
After obtaining an institutional ethics approval (#2019186), we retrospectively reviewed patients with interstitial cystitis/bladder pain syndrome (IC/BPS) who underwent hydrodistension in our hospital during January 2010 and May…
- Trial name
- NCT05221944
- Testing
- Patients had a history of antithrombotic therapy, Patients had no history of antithrombotic therapy
- Where
- China
- Volunteers
- 387 people
- Sponsor
- West China Hospital
Atrial Fibrillation
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen (Vitamin K Antagonist (VKA), Clopigogrel and Aspirin) in patients with atrial fibrillation and coronary artery disease…
- Trial name
- NCT02334254
- Testing
- rivaroxaban and ticagrel therapy, triple antithrombotic regimen with warfarin, asipirin and clopidogrel
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Anzhen Hospital
Thrombosis, Anticoagulant-induced Bleeding
Reversal of the Antithrombotic Action of New Oral Anticoagulants
The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants. 1.
- Conditions
- Thrombosis, Anticoagulant-induced Bleeding, Anticoagulant Overdosage, Hemorrhage
- Trial name
- REVANT (NCT01478282)
- Testing
- Rivaroxaban, Dabigatran
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Gines Escolar
Hemorrhage, Surgical, Hemorrhage Postoperative
Safe and Timely Antithrombotic Removal (STAR) Registry
This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Trial name
- NCT05077124
- Testing
- CytoSorb
- Where
- 29 sites in Austria, Belgium and 4 more
- Volunteers
- 1,000 people
- Sponsor
- CytoSorbents, Inc
Intracranial Hemorrhage, Traumatic, Embolism and Thrombosis
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
Oral antithrombotic medications (OAM) are used for the prevention and treatment of thrombotic disorders. Among hemorrhagic complications of OAMs, intracranial hemorrhage (ICH) may have particularly devastating consequences with…
- Conditions
- Intracranial Hemorrhage, Traumatic, Embolism and Thrombosis, Hematoma, Subdural, Intracranial
- Trial name
- NCT02996851
- Volunteers
- 6,279 people
- Sponsor
- St. Olavs Hospital
Atrial Fibrillation
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial…
- Trial name
- NCT00289042
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Acute Coronary Syndromes
EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)
This register will evaluate the use of different antithrombotic therapies, combinations of different drugs routinely used during any stage of hospital admission, with their timing, dosage and mode of administration, in patients…
- Trial name
- EYESHOT (NCT02015624)
- Where
- 203 sites in Italy
- Volunteers
- 2,597 people
- Sponsor
- Heart Care Foundation
Device-Related Thrombosis, Atrial Fibrillation
Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.
- Conditions
- Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
- Trial name
- FADE-DRT (NCT04502017)
- Testing
- ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Enoxaparin
Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®
This study is designed as a randomized, open-label, 2-way cross-over, single dose study with at least 7 days wash-out period. The objective of this study is to demonstrate the pharmacodynamic / pharmacokinetic equivalence of…
- Trial name
- NCT04402762
- Testing
- Ovine Enoxaparin, Enoxaparin Prefilled Syringe [Lovenox]
- Where
- Indonesia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Thrombosis
How Clinicians Manage Their Patients Who May Need Antithrombotic Care
This study aims to assess the knowledge and provide an opportunity for education to clinician attendees of the Canadian Cardiovascular Congress (CCC) meeting using a series of simulated patient case scenarios.
- Trial name
- NCT05923658
- Volunteers
- 2,500 people
- Sponsor
- Anthony Tang
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Coronary Artery Disease
Resistance on Antithrombotic Drugs in Ischemic Heart Disease
The purpose of this study is to determine whether aspirin and clopidogrel resistance measured with Multiplate function analyser has a good correlation with incidence of major adverse cardiac events in patients with coronary…
- Trial name
- NCT00742430
- Testing
- PCI
- Where
- Croatia
- Volunteers
- 141 people
- Sponsor
- University of Zagreb
Acute Coronary Syndrome, Atrial Fibrillation
Ongoing WARfarin and Coronary STENTing
Patients on warfarin treatment pose particular problems when undergoing percutaneous coronary intervention with stent implantation (PCI-S), because of the poor definition of the optimal antithrombotic strategies to be adopted…
- Trial name
- WAR-STENT (NCT00722319)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- War-Stent Investigators
Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia
Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB).
- Conditions
- Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia, Antithrombotic Therapy
- Trial name
- BEACON-IDA (NCT07089030)
- Testing
- Standard endoscopic evaluation, Conservative Medical Management
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Aortic Valve Disease, Heart Valve Prosthesis Implantation
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
Objectives Primary objective: To determine if rivaroxaban (Xarelto) is feasible and safe for prevention of major complications in patients undergoing a mechanical aortic heart valve replace-ment.
- Conditions
- Aortic Valve Disease, Heart Valve Prosthesis Implantation, Anticoagulants
- Trial name
- CATHAR (NCT02128841)
- Testing
- Rivaroxaban
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation, Acute Coronary Syndrome
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT01812200
- Testing
- Dabigatran, Ticagrelor, ASA, Rivaroxaban, Ticagrelor, ASA, Phenprocoumon, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Thrombosis, Myocardial Infarction
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk.
- Trial name
- DEFINE CCS (NCT05116995)
- Testing
- Rivaroxaban, Ticagrelor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Nova Scotia Health Authority
Myocardial Infarction
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks.
- Trial name
- Dan-DAPT (NCT05262803)
- Testing
- CYP2C19*2/*3, Shorter DAPT duration
- Where
- 6 sites in Denmark
- Volunteers
- 2,808 people
- Sponsor
- Rikke Sorensen
COVID-19 Pneumonia, Thrombosis
Practice Variation on Antithrombotics in COVID-19
Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations.
- Conditions
- COVID-19 Pneumonia, Thrombosis, COVID-19 Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Trial name
- NCT04998799
- Testing
- Current clinical practices of participating physicians
- Where
- India
- Volunteers
- 435 people
- Sponsor
- NMC Specialty Hospital